In particular, AhR activation promotes conversion of effector T lymphocytes into Tregs and upregulates IDO1 expression in DCs, further amplifying immunoregulatory effects and blocking anti-tumor immunity (26–28). The gene discussed is IDO1; the disease is neoplasm.